Probiotics [LGG-BB12 or RC14-GR1] versus placebo as prophylaxis for urinary tract infection in persons with spinal cord injury [ProSCIUTTU]: a study protocol for a randomised controlled trial

• Main Authors: Lee, Bonsan Bonne, Toh, Swee-Ling, Ryan, Suzanne, Simpson, Judy M., Clezy, Kate, Bossa, Laetitia, Rice, Scott A., Marial, Obaydullah, Weber, Gerard, Kaur, Jasbeer, Boswell-Ruys, Claire, Goodall, Stephen, Middleton, James, Tudehope, Mark, Kotsiou, George
• Other Authors: School of Biological Sciences
• Format: Article
• Language: English
• Published: 2016
• Subjects: Urinary prophylaxis; Microbial community profiles; Multi-resistant organisms; Antibiotic resistance; Probiotics; Biofilm
• Online Access: https://hdl.handle.net/10356/81508; http://hdl.handle.net/10220/40803
• Institution: Nanyang Technological University

Background: Urinary tract infections [UTIs] are very common in people with Spinal Cord Injury [SCI]. UTIs are increasingly difficult and expensive to treat as the organisms that cause them become more antibiotic resistant. Among the SCI population, there is a high rate of multi-resistant organism [MRO] colonisation. Non-antibiotic prevention strategies are needed to prevent UTI without increasing resistance. Probiotics have been reported to be beneficial in preventing UTIs in post-menopausal women in several in vivo and in vitro studies. The main aim of this study is to determine whether probiotic therapy with combinations of Lactobacillus reuteri RC-14 + Lactobacillus rhamnosus GR-1 [RC14-GR1] and/or Lactobacillus rhamnosus GG + Bifidobacterium BB-12 [LGG-BB12] are effective in preventing UTI in people with SCI compared to placebo.